Acetylcysteïne Dosing in acute PARacetamol intoxicatio
- Conditions
- Acute paracetamol intoxication
- Registration Number
- NL-OMON22271
- Lead Sponsor
- MCG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 2000
Inclusion Criteria
Patients with a serum level of paracetamol that is above the LOQ (5 or 10 mg/L).
Exclusion Criteria
Patients that have opted out from data collection
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of moderate (PCM4 = 100 - 150 mg/L), severe (PCM4 = 150-300 mg/L) or massive acute paracetamol intoxications (PCM4 > 300 mg/L).
- Secondary Outcome Measures
Name Time Method -Which dosing regimens for acetylcysteine are used in the Netherlands (this will be done using a survey to Dutch hospital pharmacists and is not a part of this research protocol). <br>-In moderate, severe or massive acute paracetamol intoxications:<br>oProportion of cases where treatment was prolonged after 24hrs<br>oProportion of cases with hepatotoxicity (peak ALT > 1000 U/L)<br>oProprotion of cases that have been liver transplanted<br>oProportion of fatal cases due to acute paracetamol intoxication<br>oProportion of cases with altered INR<br>oProportion of cases with adverse events to acetylcysteine that necessitate other treatment <br>oProportion of cases with manageable adverse event to acetylcysteine<br>-Possible association between PCM4 and secondary outcome parameters (treatment duration, hepatoxicity, liver transplantation, fatalities, altered INR)<br>-Possible association between acetylcysteine treatment regimen and adverse events (manageable and events that necessitate other treatment)<br>